Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
收盤時
US$0.2183
−US$0.0114 · -4.96%
盤後
US$0.2183
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日內區間
目前US$0.2183
52週區間
目前US$0.2183
盤中時間採用ET。市場資料可能有所延遲。
Accuray Incorporated specializes in the design, development, production, and sale of advanced radiosurgery and radiation therapy equipment aimed at treating tumors. Their market footprint spans across North and South America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the broader Asia Pacific region. Among their core offerings is the CyberKnife System, a sophisticated robotic platform for stereotactic radiosurgery and stereotactic body radiation therapy. This system is employed to target both primary and metastatic tumors located outside the brain, specifically addressing areas such as the spine, breast, kidney, liver, lung, pancreas, and prostate. They also provide the TomoTherapy System, which encompasses the Radixact System, designed to deliver highly precise radiation treatments (up to 50 patients daily) through integrated planning, delivery, and data management capabilities. Complementing these are the iDMS data management system and the Accuray precision treatment planning system, both offering comprehensive solutions for treatment planning and data handling. In addition to their technology, Accuray offers crucial post-sale services, including customer support, system installation, training, and various other professional services. The company primarily engages directly with its clientele, which includes hospitals and specialized treatment centers, through its dedicated sales force. In the United States, they also leverage sales agents and group purchasing organizations, while internationally, their reach extends through distributors and sales agents. Established in 1990, Accuray Incorporated maintains its corporate headquarters in Madison, Wisconsin.
日內區間
目前US$0.2183
52週區間
目前US$0.2183
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 4.02億 USD | 4.59億 USD | 4.47億 USD | 4.48億 USD | 4.3億 USD |
| 銷貨成本 | 2.9億 USD | 3.12億 USD | 3.04億 USD | 2.94億 USD | 2.7億 USD |
| 毛利 | 1.11億 USD | 1.47億 USD | 1.43億 USD | 1.54億 USD | 1.6億 USD |
| 研究與開發 | 3775.3萬 USD | 4794.2萬 USD | 4973.2萬 USD | 5712.9萬 USD | 5775.2萬 USD |
| 銷售、一般及管理費用 | 8397.1萬 USD | 9118.6萬 USD | 9268.5萬 USD | 9444.9萬 USD | 9405.5萬 USD |
| 營業費用 | 1.38億 USD | 1.39億 USD | 1.42億 USD | 1.52億 USD | 1.52億 USD |
| 利息收入 | — | 119.2萬 USD | — | — | — |
| 利息支出 | 3531萬 USD | 1295.4萬 USD | 1162.4萬 USD | 1063.2萬 USD | 812.9萬 USD |
| 折舊和攤銷 | 794.2萬 USD | 615萬 USD | 590.5萬 USD | 452.7萬 USD | 551.3萬 USD |
| 營業利益 | −2644.2萬 USD | 783.9萬 USD | 50.4萬 USD | 238.2萬 USD | 814.8萬 USD |
| 淨利 | −4919.4萬 USD | −159.1萬 USD | −1554.5萬 USD | −928萬 USD | −534.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI82.12萬0.00%2.3兆 USD0.03%US$381.57-0.10%
Fidelity Enhanced Small Cap ETFFESM33萬0.01%64.1億 USD0.28%US$45.24-0.48%
Vanguard Extended Market ETFVXF31.3萬0.00%954億 USD0.05%US$233.52-0.63%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM2.84萬0.00%6.94億 USD0.89%US$57.21-0.67%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.65萬0.00%26.7億 USD0.36%US$52.92-0.45%
Vanguard Morningstar Total Stock Market ETFVTI
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM
Invesco RAFI US 1500 Small-Mid ETFPRFZAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。